Regulatory Response to Accelerate COVID-19 Drug Development

Read more

In a recent Journal for Clinical Studies article, Aman Khera and Henry J. Riordan, Ph.D., discuss recent guidance, operational processes, and best practices designed by regulatory bodies to accelerate drug product development during COVID-19.


Chief Development Officer
VP, Regulatory Science, Strategy and Innovation

Want to learn more about Worldwide Clinical Trials?